Bristol-Myers Squibb Appoints Mike Burgess M.D., Ph.D. Senior Vice President, Discovery Medicine and Clinical Pharmacology

  Bristol-Myers Squibb Appoints Mike Burgess M.D., Ph.D. Senior Vice
  President, Discovery Medicine and Clinical Pharmacology

Business Wire

NEW YORK -- January 17, 2013

Bristol-Myers Squibb Company (NYSE: BMY) today announced that Mike Burgess
M.D., Ph.D. has joined the Company as senior vice president, Discovery
Medicine and Clinical Pharmacology. He will report to Francis Cuss, MB BChir,
FRCP, senior vice president, Research, R&D, Bristol-Myers Squibb, and will be
a member of the Research Senior Leadership Team.

“As a physician scientist with a Ph.D. in molecular biology, clinical
experience in pediatrics and pediatric oncology, and extensive pharmaceutical
industry and leadership experience, I believe Mike will be an important
addition to our research and development organization,” said Dr. Cuss. “Mike’s
broad clinical expertise, cross-therapeutic global team leadership and proven
operational excellence will enable Bristol-Myers Squibb to continue to execute
its strategy of ensuring sustainable delivery of an innovative pipeline of new
medicines for patients.”

Before joining Bristol-Myers Squibb, Dr. Burgess was interim head of Hoffman
La-Roche’s Pharma Research and Early Development organization. Prior to that
he led the Hoffman La-Roche Oncology Discovery and Translational Area, one of
five disease-focused organizations, and at the same time served as head of
Global Large Molecule Research. Before joining Hoffman La-Roche, Dr. Burgess
was at Eli Lilly and Company as a Medical Fellow. He received his medical
training and Ph.D. from the University of Bristol, U.K., and is a member of
the Royal College of Physicians and of the Royal College of Pediatrics and
Child Health.

“I am excited by the opportunity to join Bristol-Myers Squibb and its Research
Leadership Team,” said Dr. Burgess. “Bristol-Myers Squibb is well known and
respected for its innovative pipeline and approach to discovering and
developing new medicines. I am looking forward to joining this committed team
and continuing to drive research that delivers a differentiated pipeline of
potential new medicines.”

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to
discover, develop and deliver innovative medicines that help patients prevail
over serious diseases. For more information, please visit or
follow us on Twitter at


Bristol-Myers Squibb
Jennifer Fron Mauer, 609-252-6579;
Investors: John Elicker, 609-252-4611;
Press spacebar to pause and continue. Press esc to stop.